AxoGen Akcija

AxoGen EV/FCF

Vrijednost EV/FCF (Вредност предузећа према слободном готовинском току) od AxoGen (AXGN) na dan 21. авг 2026. je -583,89. Prethodne godine, EV/FCF (Вредност предузећа према слободном готовинском току) je bio 155.791,09 — promjena od -100,37% (niži).

EV/FCF

-583,89

YoY

-100,37%

Zadnja ažuriranja:

EV/FCF (Вредност предузећа према слободном готовинском току) od AxoGen je 2026 -583,89 . EV/FCF (Вредност предузећа према слободном готовинском току) od AxoGen je bio 2025 155.791,09 . Pad je time -100,37% niži u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

AxoGen Анализа акција

Šta radi AxoGen? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji AxoGen

EV/FCF (Вредност предузећа према слободном готовинском току) kompanije AxoGen iznosi -583,89 u 2026. godini.

EV/FCF (Вредност предузећа према слободном готовинском току) od AxoGen se promijenio sa 155.791,09 na -583,89, što predstavlja promjenu od -100,37%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EV/FCF (Вредност предузећа према слободном готовинском току) AxoGen od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Однос EV/FCF мери вредност предузећа у односу на слободан готовински ток и обухвата праву генерисање готовине пословања.

Da biste proverili EV/FCF (Вредност предузећа према слободном готовинском току)'s, bitno je da ga uporedite sa konkurentima u istoj industriji i sektoru. Na Eulopoolu, možete pronaći direktna upoređivanja industrije za EV/FCF (Вредност предузећа према слободном готовинском току).

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti EV/FCF (Вредност предузећа према слободном готовинском току)'s AxoGen sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Access this data via the Eulerpool API

Вредновање — AxoGen

Sve ključne metrike — AxoGen

Раст